Bajaj Healthcare (BHL) has received FDA approval for manufacturing Hydroxychloroquine Sulphate Bulk Drug (API) and formulation for its tablets. Hydroxychloroquine Sulphate has been recommended by several countries, including the US, with limited dosage for Covid-19 patients and as a-preventive for high-risk individuals like healthcare workers.
The company will commence its own production of Hydroxychloroquine Sulphate API in the next 3 weeks at its state-of-art manufacturing facilities based at Vadodara, Gujarat and it is estimate to produce 15 Mts of API per month. The company has started the production of Hydroxychloroquine FDF (Tablets ) at Vadodara, Gujarat and is estimated to produce approximately 15 million tablets of Hydroxychloroquine Sulphate.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
